Supernus Pharmaceuticals' ONAPGO for Parkinson’s Disease received FDA approval, providing a basis for optimism despite past regulatory challenges with SPN-830. The company is methodically ...
Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of Parkinson’s disease. Supernus’ regulatory path for Onapgo has been ...
Investors might want to bet on Supernus Pharmaceuticals (SUPN), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in ...
The FDA has approved Supernus Pharmaceuticals’ Onapgo (apomorphine hydrochloride) injection, the first and only subcutaneous apomorphine infusion device for managing motor fluctuations in adults with ...
Super Micro Computer stock was rising ahead of Thursday’s opening bell, putting the artificial intelligence server maker on course for further gains. It’s finally giving investors reason to feel ...
Supernus has boosted its position in central nervous system therapies with a $400 million deal to acquire Adamas Pharma that will add two approved Parkinson's disease therapies to its stable.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...